RAD140 is an investigational
selective androgen receptor modulator (SARM) that is developed by Radius Health, Inc. for use in
androgen replacement therapy
Androgen replacement therapy (ART), often referred to as testosterone replacement therapy (TRT) or hormone replacement therapy (HRT), is a form of hormone therapy in which androgens, often testosterone, are supplemented or replaced exogenously ...
. It was licensed to Ellipses Pharmaceuticals in 2020.
Some of the potential benefits under investigation are for the treatment of conditions such as
muscle wasting and
bone loss
Osteoporosis is a systemic skeletal disorder characterized by low bone mass, micro-architectural deterioration of bone tissue leading to bone fragility, and consequent increase in fracture risk. It is the most common reason for a broken bone ...
.
Clinical trials
The first-in-human study was initiated in October of 2017 and completed in September 2020 in
postmenopausal women with
breast cancer
Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a re ...
.
In early 2020 a single case report of
drug-induced liver injury following use of RAD 140 was published.
Animal studies
RAD 140 appears to be safer than testosterone replacement therapy (TRT) in rats.
RAD 140 slightly increased lean muscle mass when used in primates, by targeting androgen receptors in skeletal tissue.
See also
*
AC-262,356
*
BMS-564,929
*
Enobosarm
*
LGD-2226
LGD-2226 is an investigational selective androgen receptor modulator (SARM), which is being developed for treatment of muscle wasting and osteoporosis.
LGD-2226 is an orally active, potent and selective agonist for androgen receptors which w ...
*
LGD-4033
Ligandrol (VK5211, LGD-4033) is a novel nonsteroidal oral selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis, discovered by Ligand Pharmaceuticals and under development by Viking Thera ...
*
S-23
*
S-40503
S-40503 is an investigational selective androgen receptor modulator (SARM) developed by the Japanese company Kaken Pharmaceuticals, which was developed for the treatment of osteoporosis. SARMs are a new class of drugs which produce tissue-speci ...
References
Chloroarenes
Designer drugs
Nitriles
Selective androgen receptor modulators
{{genito-urinary-drug-stub